#Japan #Osaka #Bayer Pharmaceuticals #Daiichi Sankyo Healthcare #Claritin EX

Bayer and Daiichi Sankyo Healthcare Collaborate on Claritin® EX

In a significant move within the healthcare sector, Bayer Pharmaceuticals and Daiichi Sankyo Healthcare have announced a licensing agreement for Claritin® EX, an antihistamine drug aimed at treating allergic rhinitis, effective from July 1 of this year. This collaboration marks a pivotal moment in enhancing access to allergy relief solutions across Japan.

About Claritin® EX

Claritin® EX contains the active ingredient loratadine, classified as a second-generation antihistamine. Its formulation is designed to minimize drowsiness, making it a preferable choice for individuals suffering from symptoms of allergic rhinitis, such as sneezing, runny nose, and nasal congestion. The recommended dosage is one tablet per day, which ensures sustained effectiveness throughout the day and helps to reduce the chances of missed doses.

This non-sedating antihistamine has established a strong global reputation, having improved the quality of life (QOL) for many individuals facing allergy issues in various parts of the world. Its long-standing success in treating allergies has made it a staple for those dealing with the challenges of allergic reactions, particularly in seasonal allergies like hay fever.

Objectives and Background of the Partnership

Bayer Pharmaceuticals brings extensive global expertise in the healthcare sector along with significant experience in enhancing the product value of Claritin® EX. Through this partnership, Bayer aims to leverage Daiichi Sankyo Healthcare's insights in the over-the-counter (OTC) pharmaceutical market and its extensive distribution network. This collaboration aims to more effectively deliver Claritin® EX to those in need, further advancing the self-care market landscape within Japan’s allergy sector.

Daiichi Sankyo Healthcare has long been establishing products within the OTC segment, particularly focusing on allergy medications. By incorporating Claritin® EX into its portfolio, the company aims to bolster its presence in the allergy medication domain. Allergies often lead to discomforting symptoms like sneezing and nasal congestion, and with the increasing presence of allergens such as pollen in daily life, addressing these health concerns has become pivotal for many individuals.

Moreover, the increasing societal focus on self-care highlights the importance of enabling consumers to choose the right medications for their needs. Daiichi Sankyo Healthcare is committed to utilizing its wealth of knowledge in pharmaceuticals to create an environment that allows consumers to select and use medications responsibly and effectively based on their symptoms.

Through this agreement, both companies are determined to facilitate access to Claritin® EX for a broader audience suffering from allergic symptoms. By actively promoting self-care and self-medication in the allergy sector, the duo aims to make significant contributions to public health and well-being.

About Daiichi Sankyo Healthcare

Daiichi Sankyo Healthcare positions itself as a leading company within the OTC pharmaceuticals sphere, capitalizing on its strengths to expand into functional skincare, oral care, and nutrition segments. Their corporate slogan, “Fit for You: A Partner for Healthy Lives,” embodies their mission to ensure a society where self-care is safe and encouraged for all individuals.

About Bayer Pharmaceuticals

Bayer Pharmaceuticals is dedicated to transformational healthcare solutions for patients in Japan through its diverse sectors, including prescription medications and consumer health products. The company prioritizes specialties such as cardiology, nephrology, metabolism, oncology, and ophthalmology, focusing on innovative treatments to extend the healthspan and quality of life for aging populations. For more information, visit Bayer Pharmaceuticals Japan or check out their social media channels on Facebook and YouTube.